Bayer is the pharmaceuticals company most prolific at making international expansions, followed by Novartis and E. Merck. GlobalData’s pharmaceuticals foreign direct investment (FDI) company report highlights the current foreign investments made by leading pharmaceuticals investors. Buy the report here.

Bayer has been the most active pharmaceuticals greenfield investor between Q1 2019 and Q4 2023, according to GlobalData’s FDI Projects Database. The Parent_clean company has been actively investing through several of its subsidiaries/company divisions.

Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.

The majority of Bayer investments were in the drug manufacturers subsector. In fact, 71% of its total foreign investments were in this subsector. It also created projects across a further 8 subsectors.

By business function, most (41.9%) of Bayer projects were related to manufacturing. R&D and Healthcare provision were the next most popular operations undertaken by Bayer.

The company has been active across eight world regions, mainly focused on Asia which received 25.8% of the company’s greenfield investments between Q1 2019 and Q4 2023. Its top three destination countries (by number of greenfield FDI projects) were India, the US and Spain. Combined these three countries account for 59.1% of its total number of pharmaceuticals investments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bayer created more FDI projects in 2022 compared to any other year between Q1 2019 and Q4 2023.

Other leading FDI project generators in the pharmaceuticals industry include Novartis, E. Merck, AstraZeneca and Sanofi.

The US is the leading source market for outbound pharmaceuticals greenfield FDI projects. The country accounts for 25.6% of total outbound pharmaceuticals investment projects. There have been 148 unique parent companies from the US that have announced pharmaceuticals FDI projects between between Q1 2019 and Q4 2023.

To further understand the top pharmaceuticals FDI companies, access GlobalData’s Top Pharmaceuticals Foreign Direct Investment Companies report.